Aytu BioScience Inc.
| NASDAQ: AYTU | Healthcare / Biotechnology / USA |
| 2.93 | +0.0200 | +0.69% | Vol 158.45K | 1Y Perf 1 432.39% |
| Oct 3rd, 2023 15:59 DELAYED |
| BID | 2.92 | ASK | 3.00 | ||
| Open | 2.91 | Previous Close | 2.91 | ||
| Pre-Market | 2.79 | After-Market | - | ||
| -0.12 -4.12% | - - |
| Target Price | 5.50 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 87.71 | Finscreener Ranking | ★★★+ 51.99 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★+ 42.77 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★ 39.49 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 44.29 | Earnings Rating | Neutral | |
| Market Cap | 11.08M | Earnings Date | 13th Nov 2023 | |
| Alpha | -0.06 | Standard Deviation | 0.32 | |
| Beta | -0.37 |
Today's Price Range 2.783.20 | 52W Range 1.384.88 | 5 Year PE Ratio Range -1.50-0.3000 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 76.36% | ||
| 1 Month | 70.18% | ||
| 3 Months | 65.34% | ||
| 6 Months | 22.27% | ||
| 1 Year | 1 432.39% | ||
| 3 Years | -75.95% | ||
| 5 Years | -88.41% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -47.03 | |||
ROE last 12 Months | -103.02 | |||
ROA (5Y Avg) | -8.26 | |||
ROA last 12 Months | -45.11 | |||
ROC (5Y Avg) | -134.23 | |||
ROC last 12 Months | -80.00 | |||
Return on invested Capital Q | -4.09 | |||
Return on invested Capital Y | -95.72 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 1.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.10 | ||||
| 0.24 | ||||
| 0.15 | ||||
| - | ||||
| -0.50 | ||||
| -1.08 | ||||
| -0.86 | ||||
| 3.96 | ||||
| 11.89M | ||||
| Forward PE | -3.46 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.70 | ||||
| 1.00 | ||||
| 0.20 | ||||
| 0.42 | ||||
| - | ||||
| Leverage Ratio | 2.90 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 56.50 | ||||
| -28.80 | ||||
| -19.10 | ||||
| -289.70 | ||||
| -92.88 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 79.30M | ||||
| 23.32 | ||||
| 74.01 | ||||
| 105.62 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2023 | - | 0.16 | - |
| Q03 2023 | - | -1.93 | - |
| Q02 2023 | 0.20 | -1.31 | -755.00 |
| Q01 2023 | - | -1.20 | - |
| Q04 2022 | -4.80 | -5.00 | -4.17 |
| Q03 2022 | -8.20 | -5.40 | 34.15 |
| Q02 2022 | - | -8.80 | - |
| Q01 2022 | - | -6.60 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2023 QR | -1.54 | 75.32 | Positive |
| 6/2023 QR | -1.80 | 0.00 | - |
| 6/2023 FY | -6.22 | - | - |
| 6/2024 FY | -0.78 | - | - |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 158.45K |
| Shares Outstanding | 3.78K |
| Shares Float | 2.56M |
| Trades Count | 724 |
| Dollar Volume | 468.62K |
| Avg. Volume | 656.12K |
| Avg. Weekly Volume | 1.46M |
| Avg. Monthly Volume | 375.79K |
| Avg. Quarterly Volume | 135.82K |
Aytu BioScience Inc. (NASDAQ: AYTU) stock closed at 2.91 per share at the end of the most recent trading day (a 7.78% change compared to the prior day closing price) with a volume of 265.24K shares and market capitalization of 11.08M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 75 people. Aytu BioScience Inc. CEO is Joshua R. Disbrow.
The one-year performance of Aytu BioScience Inc. stock is 1432.39%, while year-to-date (YTD) performance is 1439.68%. AYTU stock has a five-year performance of -88.41%. Its 52-week range is between 1.38 and 4.88, which gives AYTU stock a 52-week price range ratio of 44.29%
Aytu BioScience Inc. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 0.24, a price-to-sale (PS) ratio of 0.15, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -45.11%, a ROC of -80.00% and a ROE of -103.02%. The company’s profit margin is -92.88%, its EBITDA margin is -19.10%, and its revenue ttm is $79.30 Million , which makes it $23.32 revenue per share.
Of the last four earnings reports from Aytu BioScience Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Aytu BioScience Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Aytu BioScience Inc. is Strong Buy (1), with a target price of $5.5, which is +87.71% compared to the current price. The earnings rating for Aytu BioScience Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aytu BioScience Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aytu BioScience Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.05, ATR14 : 0.20, CCI20 : 267.28, Chaikin Money Flow : 0.65, MACD : 0.20, Money Flow Index : 99.33, ROC : 90.20, RSI : 85.99, STOCH (14,3) : 93.92, STOCH RSI : 1.00, UO : 69.19, Williams %R : -6.08), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aytu BioScience Inc. in the last 12-months were: Greg Pyszczymuka (Buy at a value of $24 480), Joshua R. Disbrow (Buy at a value of $77 662), Mark K. Oki (Buy at a value of $20 700), Pyszczymuka Greg (Buy at a value of $22 440), Pyszczymuka Greg (Sold 0 shares of value $0 )
Aytu BioScience Inc.
Aytu BioScience Inc is a specialty pharmaceutical company commercializing novel products addressing patient needs. The company markets a portfolio of prescription products addressing large therapeutic markets. The primary care portfolio includes Natesto, the only FDA-approved nasal formulation of testosterone, ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes AcipHex Sprinkle, Cefaclor, Karbinal ER, and Poly-Vi-Flor and Tri-Vi-Flor.
CEO: Joshua R. Disbrow
Telephone: +1 720 437-6580
Address: 373 Inverness Parkway, Englewood 80112, CO, US
Number of employees: 75
TipRanks News for AYTU
Fri, 29 Sep 2023 15:16 GMT Transition to Profitability: Aytu BioSciences Financial Turnaround Driven by ADHD Franchise and Strategic Cost Reductions
- TipRanks. All rights reserved.
